Härd, Torleif
- Department of Molecular Sciences, Swedish University of Agricultural Sciences
Abstract
The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as Screening reagents or antigens in methods
and pharmaceutical preparations for the treatment of
Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to
the invention replaced by cysteins, which results in an intra
molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.
SLU Authors
UKÄ Subject classification
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
More information
Assignees: HÄRD, Torleif [SE/SE]; SE (UsOnly) SANDBERG, Anders [SE/SE]; SE (UsOnly) MIVAC DEVELOPMENT AKTIEBOLAG [SE/SE]; Göteborg, SE (AllExceptUS)
Permanent link to this page (URI)
https://res.slu.se/id/publ/66724